OTCMKTS:PURE PURE Bioscience (PURE) Stock Price, News & Analysis $0.06 -0.01 (-14.29%) As of 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About PURE Bioscience Stock (OTCMKTS:PURE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PURE Bioscience alerts:Sign Up Key Stats Today's Range$0.06▼$0.0750-Day Range$0.06▼$0.0952-Week Range$0.04▼$0.10Volume38,070 shsAverage Volume21,423 shsMarket Capitalization$7.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PURE Bioscience develops and commercializes antimicrobial products based on silver dihydrogen citrate (SDC), a proprietary formulation designed to control bacteria and other microorganisms. The company focuses on applications where surface hygiene and food safety are important. Its offerings include SDC-based disinfectant and sanitizer products for hard surfaces, including products intended for food-processing and food-service environments. PURE Bioscience also pursues commercial partnerships to market its technology and products. The company’s business centers on developing uses for its SDC technology across professional settings such as food handling and sanitation. Product availability and applications may vary by market and regulatory requirements.AI Generated. May Contain Errors. Read More PURE Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScorePURE MarketRank™: 1.45430463576 of 5 starsPURE Bioscience scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for PURE Bioscience. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PURE Bioscience is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PURE Bioscience is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of PURE Bioscience has been sold short.Short Interest Ratio / Days to CoverPURE Bioscience has a short interest ratio ("days to cover") of 0.07, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PURE Bioscience has recently decreased by 54.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPURE Bioscience does not currently pay a dividend.Dividend GrowthPURE Bioscience does not have a long track record of dividend growth. News and Social Media3.8 / 5News SentimentN/A News SentimentPURE Bioscience has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for PURE Bioscience this week, compared to 0 articles on an average week.Search Interest1 people have searched for PURE on MarketBeat in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PURE Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders35.56% of the stock of PURE Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPURE Bioscience has minimal institutional ownership at this time.Read more about PURE Bioscience's insider trading history. Receive PURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PURE Stock News HeadlinesPurecore Adds Jeremy S. Brett as Technical AdvisorNovember 5, 2026 | globenewswire.comPURE Bioscience, Inc. Reports Earnings Results for the Full Year Ended July 31, 2026October 31, 2026 | marketscreener.comMMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 16 at 1:00 AM | Profits Run (Ad)PURE Bioscience Reports Fiscal 2026 Financial ResultsOctober 29, 2026 | finance.yahoo.comPurecore Publishes Uranium Market Report Tracking AI-Driven Nuclear DemandOctober 27, 2026 | globenewswire.comPURE Bioscience completes insider-led private equity financingOctober 20, 2026 | tipranks.comPure Bioscience Inc.August 12, 2026 | marketwatch.comPURE Bioscience Reports Fiscal Third Quarter 2026 Financial ResultsJune 15, 2026 | businesswire.comSee More Headlines PURE Stock Analysis - Frequently Asked Questions How have PURE shares performed this year? PURE Bioscience's stock was trading at $0.0420 at the beginning of the year. Since then, PURE stock has increased by 42.9% and is now trading at $0.06. How were PURE Bioscience's earnings last quarter? PURE Bioscience (OTCMKTS:PURE) posted its quarterly earnings data on Monday, June, 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $510 thousand for the quarter. How do I buy shares of PURE Bioscience? Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PURE Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that PURE Bioscience investors own include Aurora Cannabis (ACB), Novavax (NVAX), Cresco Labs (CRLBF), Aurora Cannabis (ACB), Canopy Growth (CGC), DraftKings (DKNG) and Broadcom (AVGO). Company Calendar Today11/16/2026Fiscal Year End7/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryN/A Current SymbolOTCMKTS:PURE CIK1006028 Webwww.purebio.com Phone(619) 596-8600Fax619-596-8790Employees11Year Founded1992Profitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.48 million Net Margins-107.12% Pretax Margin-107.12% Return on EquityN/A Return on Assets-210.20% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick Ratio0.23 Sales & Book Value Annual Sales$2.32 million Price / Sales3.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-1.20Miscellaneous Outstanding Shares130,020,000Free Float83,784,000Market Cap$7.80 million OptionableNot Optionable Beta0.34 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:PURE) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman and Jensen Huang could one day be worth more than Ap...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PURE Bioscience Please log in to your account or sign up in order to add this asset to your watchlist. Share PURE Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.